Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Johnson and Johnson
Medtronic
McKinsey
Moodys

Last Updated: November 16, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,384,020

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,384,020
Title: Rapid immediate release oral dosage form
Abstract:A pharmaceutical composition comprising lactitol and one or more amphetamine salts in a rapid release formulation.
Inventor(s): Flanner; Henry H. (Montgomery Village, MD), Chang; Rong-Kun (Rockville, MD), Pinkett; Jill E. (Baltimore, MD), Wassink; Sandra E. (Frederick, MD), White; Lisa R. (Damascus, MD)
Assignee: Shire Laboratories, Inc. (Rockville, MD)
Application Number:09/611,098
Patent Claim Types:
see list of patent claims
Composition; Dosage form;

Drugs Protected by US Patent 6,384,020

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Teva Womens ADDERALL 10 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate TABLET;ORAL 011522-007 Feb 13, 1996 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Teva Womens ADDERALL 12.5 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate TABLET;ORAL 011522-012 Aug 31, 2000 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Teva Womens ADDERALL 15 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate TABLET;ORAL 011522-013 Aug 31, 2000 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Teva Womens ADDERALL 20 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate TABLET;ORAL 011522-008 Feb 13, 1996 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Teva Womens ADDERALL 30 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate TABLET;ORAL 011522-010 May 12, 1997 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,384,020

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 6089200   Start Trial
Canada 2378336   Start Trial
European Patent Office 1202739   Start Trial
Japan 2003504406   Start Trial
Mexico PA02000290   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Johnson and Johnson
Harvard Business School
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.